Go here to read the rest:
Stephen Bardin to Join atai Life Sciences as CFO Designate
Author Archives: Fredricko
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
Quotient Limited to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on June 22nd
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022
Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
ExCellThera announces submission of Drug Master File for UM171
Go here to see the original:
ExCellThera announces submission of Drug Master File for UM171
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular…
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types…
BioCorRx Featured on LiveNOW from FOX
Read more:
BioCorRx Featured on LiveNOW from FOX
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Genmab Announces Initiation of Share Buy-Back Program
Continued here:
Genmab Announces Initiation of Share Buy-Back Program
BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
See the original post here:
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice